Antonio Passaro MD PhD is medical oncologist at the Division of Thoracic Oncologist of the European Institute of Oncology in Milan, Italy.

He is a clinician and researcher specialised in lung cancer, with a PhD in molecular medicine. Driven by a dedication to advancing patient care, his main areas of interest encompass the development of new therapeutics for lung cancer, ranging from target agents to immunotherapy, across all stages of disease. Dr. Passaro's expertise extends to the evaluation and validation of novel reliable biomarkers for non-small cell lung cancer (NSCLC) which represent a key to prognosis, and prediction of treatment response.

Dr. Passaro actively contributes to the advancement of lung cancer research through his participation in various research projects and clinical trials. As a local principal investigator (PI) for lung trials at the European Institute of Oncology, he assumes a leadership role in assessing the efficacy and safety of emerging therapeutic agents. Furthermore, Dr. Passaro serves as a steering committee member for multiple international phase 3 trials.

Dr. Passaro has authored more than 100 peer-reviewed manuscripts. He also serves as an Associate Editor of the Lung Cancer Journal and holds positions on the editorial boards of several other oncology journals.

Dr. Passaro covers many key roles in professional societies. He is a member of the ESMO Council by virtue of being the Chair of the ESMO Communication Committee. He holds a position in the ESMO Non-metastatic NSCLC and other thoracic malignancies Faculty and has contributed to the development of the ESMO Clinical Practice Guidelines for the management of lung cancer. Dr. Passaro is a board member for lung cancer guidelines of the Italian Association of Medical Oncology (AIOM).